EndoLogic Announces FDA Accepts Cardiac Safety Trial for Renzapride in Patients with Gastroparesis Study demonstrates no evidence of QTc prolongation EndoLogic remains on plan to initiate 12-week renzapride Phase 2 trial pending collaboration with a development partner CLIFTON, N.J., May 15,...

EndoLogic Announces Feedback from Positive FDA Meeting for Renzapride in Diabetic Gastroparesis FDA pre-IND meeting minutes describe steps required for new drug application (NDA) submission No additional toxicology studies required to initiate Phase 2 trial EndoLogic will move forward with a...

EndoLogic Announces Scheduling of pre-IND Meeting with FDA to Discuss Renzapride in Diabetic Gastroparesis CLIFTON, N.J., May 03, 2017 (GLOBE NEWSWIRE) -- EndoLogic, a company focused on the development and commercialization of products that treat gastrointestinal diseases, announced that the FDA has...

EndoLogic Acquires Renzapride from Alizyme, plc CLIFTON, N.J., Jan. 03, 2017 (GLOBE NEWSWIRE) -- EndoLogic, a company focused on the development and commercialization of products that treat gastrointestinal diseases, has acquired the worldwide...